SMS Pharmaceuticals Limited — Results, 31-07-2026: Integrated Filing- Financial

SMS Pharmaceuticals reported consolidated Q1FY27 revenue of 206.96 Cr, up 5.56% YoY, driven by its Active Pharmaceutical Ingredients (API) segment. Net Profit increased modestly by 2.05% YoY to 20.91 Cr, but saw a 36.10% QoQ decline. EPS for the quarter was 2.23, down from 2.31 YoY, partly due to increased outstanding shares. While cost of materials decreased YoY, employee benefits expenses rose.

The company has announced a board meeting outcomes, including the re-appointment of Mr. Ramesh Babu Potluri as Chairman & MD for five years and approval for a 50 Cr loan to subsidiary SMS Peptides Private Limited for business needs, both awaiting shareholder approval. An AGM is scheduled for September 23, 2026, with Sep 16, 2026, as the record date for dividends.

Overall, Q1 FY27 results reflect mixed financial momentum with steady revenue growth but fluctuating profitability.